Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

OGI Investment will Fund Proteomic and Transcriptomic Analyses to Further Understand Stem Cells

Published: Thursday, November 15, 2012
Last Updated: Thursday, November 15, 2012
Bookmark and Share
The investment will be used to conduct studies required to apply for approval to initiate human clinical trials.

The Ontario Genomics Institute (OGI), through its Pre-Commercialization Business Development Fund (PBDF), has invested in Toronto-based Tissue Regeneration Therapeutics (TRT), a company that aims to use umbilical mesenchymal stem cells (MSCs) to treat a variety of serious medical conditions. 

MSCs are cells that can differentiate into musculoco-skeletal tissues such as bone, cartilage and muscle. Their ability to generate replacement tissues and affect cellular processes such as inflammation makes them an exciting potential therapy for a variety of conditions. Unlike other cells, MSCs can be used without the need for tissue matching and can be accumulated in large numbers. TRT has developed new methods to extract MSCs from umbilical cords, eliminating many of the challenges related to MSC harvesting from other tissue sources. 

“Stem cell research is a promising area of biomedical research and it could have significant impact for people suffering from many conditions,” said Mark Poznansky, President and CEO, OGI. “TRT is an excellent example of an Ontario company developing innovative therapies and translating research into potential clinical applications.”

TRT is aiming to launch clinical trials to test these cells within the next two years.  The PBDF funding from OGI will fund proteomic and transcriptomic analyses to further understand TRT’s stem cells. These studies will provide valuable information needed for regulatory approval to conduct human clinical trials and further differentiate their product from those of competitors.

“We believe that these stem cells represent a unique and potent means of treating multiple debilitating diseases,” said John Davies, CEO of TRT. “The OGI funding will enable us to demonstrate the utility of our cells for clinical applications using cutting edge technologies.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Rare Immunodeficiency Yields Unexpected Insights
Scientists uncover previously unknown gene mutation revealing the role of a key molecule involved in immune cell development.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
IU Research Reveals Link between Molecular Mechanisms in Prostate Cancer and Ewing's sarcoma
Researchers at IU have suggested that the molecular mechanism that triggers the rare disease Ewing's sarcoma could act as a potential new direction for the treatment of more than half of patients with prostate cancer.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
RNA-Binding Proteins Role in ALS Revealed
Researchers describe how damage to RNA-binding protein contributes to ALS, isolating a possible therapeutic target.
Advances in Alzheimer’s Research
Researchers show how a diseased vertebrate brain can naturally react to Alzheimer’s pathology by forming more neurons.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Alzheimer’s-Linked Protein May Play Role in Schizophrenia
Researchers suggests a protein linked to cognitive decline in Alzheimer's also plays a role in genetic predisposition to schizophrenia.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos